CDDW Abstracts 2008
Return to Main Menu
Search CDDW 2008 Abstracts
POSTER SESSION I - IMMUNOLOGY AND INFLAMMATORY BOWEL DISEASE
060 - TOXIC MEGACOLON IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE: CLINICAL AND RADIOGRAPHIC CHARACTE...
061 - IS THERE A NEED FOR DENTAL CHECKUP PRIOR TO INFLIXIMAB INFUSION? A CASE REPORT AND REVIEW OF LI...
062 - INFLIXIMAB FOR ANTI-CTLA 4 ANTIBODY INDUCED COLITIS
063 - EFFICACY OF INFLIXIMAB THERAPY FOR SEVERE ULCERATIVE COLITIS
064 - IDENTICAL TWIN BROTHERS WITH UC AND DISCORDANT HEPATOBILIARY MANIFESTATIONS OF IBD
065 - A SINGLE-CENTRE EXPERIENCE WITH INFLIXIMAB IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH SEVER...
066 - RELAPSING POLYCHONDRITIS IN A PATIENT WITH ULCERATIVE COLITIS: A CASE REPORT
067 - PULMONARY CROHN’S DISEASE SUCCESSFULLY TREATED WITH INFLIXIMAB
068 - HIGH RESOLUTION ABDOMINAL ULTRASONOGRAPHY IN CROHN’S DISEASE: DEGREE OF CORRELATION WITH ENDOSC...
069 - LIFE-THREATENING COMPLICATIONS OF SULPHASALAZINE THERAPY IN PAEDIATRIC INFLAMMATORY BOWEL DISEA...
070 - INFLIXIMAB MAINTENANCE THERAPY IN PEDIATRIC CROHN’S DISEASE: THE IMPACT OF DISCONTINUATION OF C...
071 - THE UTILITY AND SIGNIFICANCE OF RIGHT COLON BIOPSIES OBTAINED DURING SURVEILLANCE FOR COLON CAN...
072 - INTESTINAL EXPRESSION AND FUNCTIONAL ANALYSIS OF ORGANIC CATION / L-CARNITINE TRANSPORTER (OCTN...
073 - DE NOVO IBD OCCURING AFTER ORTHOTOPIC LIVER TRANSPLANTATION
074 - THE EXTRACELLULAR ATP RECEPTOR P2X7 IS INCREASED IN MURINE TNBS COLITIS
075 - THE CANNABINOID-2 (CB2) RECEPTOR AGONIST AM1241 MEDIATES PROTECTION AGAINST TNBS COL...
076 - PRE-POUCH ILEITIS AFTER COLECTOMY IN PEDIATRIC ULCERATIVE COLITIS
077 - DELINEATION OF THE EARLY EVENTS IN THE PATHOGENESIS OF DEXTRAN SULPHATE INDUCED COLITIS
078 - ELICITING AN IMMUNE MEMORY RESPONSE TO H. DIMINUTA AS A MEANS TO TREAT MURINE COLITIS EV...
079 - INFLIXIMAB USE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND THE RISK OF HOSPITALIZED CLOS...
080 - MMX™ MESALAMINE AS THE SOLE MEDICATION FOR THE INDUCTION OF REMISSION AND PREVENTION OF RELAPSE...
081 - PROLONGED THERAPY WITH MMX™ MESALAMINE FOR THE INDUCTION OF REMISSION OF ACTIVE, MILD-TO-MODERA...
082 - MMX™ MESALAMINE MAINTAINS REMISSION FOR AT LEAST 12 MONTHS IN PATIENTS WITH MILD-TO-MODERATE UL...
083 - ULCERATIVE COLITIS (UC) IS REPORTED TO HAVE A GREATER IMPACT ON PATIENTS’ (PTS) LIVES COMPARED ...
084 - PATIENTS (PTS) AND PHYSICIANS HAVE DIFFERENT PERCEPTIONS OF DISEASE SEVERITY IN ULCERATIVE COLI...
085 - IMPACT OF ADALIMUMAB THERAPY ON PATIENT-REPORTED OUTCOMES IN CROHN’S DISEASE
086 - IMPACT OF ADALIMUMAB MAINTENANCE THERAPY ON PATIENT-REPORTED OUTCOMES IN FISTULIZING CROHN’S DI...
087 - TRADITIONAL CORTICOSTEROIDS FOR INDUCTION OF REMISSION IN CROHN DISEASE: A SYSTEMATIC REVIEW AN...
088 - REDUCING SMALL INTESTINAL PERMEABILITY ATTENUATES COLITIS IN THE IL-10 GENE DEFICIENT MOUSE
089 - THE ROLE OF GROUP IV PTK IN TNBS-COLITIS MODEL
090 - THE INCREASE IN P2Y2 NUCLEOTIDE RECEPTOR EXPRESSION IS REGULATED AT THE TRANSCRIPTIO...
091 - IN VITRO INFECTIVITY OF HEPATITIS C VIRUS FROM PLASMA AND LYMPHOID CELLS OF PATIENTS WITH THERA...
092 - HISTONE ACETYLTRANSFERASE IS INVOLVED IN PROTEINASE-ACTIVATED RECEPTOR (PAR)-INDUCED INTERLEUKI...
093 - URINARY METABOLOMIC PROFILES DIFFER BETWEEN PATIENTS WITH AND WITHOUT INFLAMMATORY BOWEL DISEAS...
094 - PHENOTYPIC CHARACTERISTICS OF INFLAMMATORY BOWEL DISEASE (IBD) IN FRENCH CANADIANS: COMPARISON ...
095 - TYPE I INTERFERONS FOR THE INDUCTION OF REMISSION IN ULCERATIVE COLITIS – A SYSTEMATIC REVIEW &...
096 - BUDESONIDE FOR THE INDUCTION OF REMISSION IN CROHN’S DISEASE – A SYSTEMATIC REVIEW & METANA...
097 - ORAL B12 IN CROHN’S DISEASE: IS B12 BY INJECTION OBSOLETE?
098 - COLECTOMY RATE FOR ULCERATIVE COLITIS IN SOUTHWESTERN ONTARIO
099 - INFLIXIMAB FOR THE TREATMENT OF HOSPITALIZED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
100 - CROHN’S DISEASE IN CYSTIC FIBROSIS
101 - SUSTAINABLE FISTULA HEALING AND RESPONSE WITH ADALIMUMAB: 2-YEAR DATA FROM CHARM AND 12-MONTH O...
102 - SAFETY OF ADALIMUMAB MAINTENANCE THERAPY IN CROHN’S DISEASE (CD): OPEN-LABEL FOLLOW-UP OF THE G...
103 - PROTECTIVE EFFECT OF CYTOKINES AGAINST OXIDATIVE DAMAGE TO ENTERIC NEURONS IN VITRO
104 - ORAL ADMINISTRATION OF CURCUMIN HAS A POTENT ANTI-INFLAMMATORY EFFECT IN THE IL-10 GENE-DEFICIE...
105 - REGULATION OF LEUKOCYTES TRAFFICKING TO THE INTESTINAL EPITHELIUM BY EXTRACELLULAR NUCLEOTIDES
106 - EVALUATION OF A WHOLE BLOOD-BASED RAPID TEST FOR TRANSGLUTAMINASE DETECTION IN CELIAC DISEASE
107 - INDUCTION OF HEALTH-RELATED QUALITY OF LIFE (HRQoL) RESPONSE AND REMISSION IN CROHN’S DISEASE (...
108 - RAPID SYMPTOM RESOLUTION WITH DELAYED RELEASE MESALAMINE IN MILDLY AND MODERATELY ACTIVE UC
109 - RAPID CLINICAL REMISSION IS SIGNIFICANT FOR THE WELL-BEING OF ULCERATIVE COLITIS PATIENTS TREAT...
110 - PREVIOUS HISTORY OF STEROID USE DOES NOT PRECLUDE TREATMENT WITH MESALAMINE IN ULCERATIVE COLIT...
111 - COMPARABLE PHARMACOKINETICS OF TWO DELAYED RELEASE FORMULATIONS OF ORAL MESALAMINE
112 - RAPID ONSET OF RESPONSE AND REMISSION TO SUBCUTANEOUS (SC) CERTOLIZUMAB PEGOL (CZP) AND LACK OF...
113 - THE ROLE OF CADHERINS IN IBD
114 - INTESTINAL EPITHELIAL CELLS MODULATE DENDRITIC CELL ACTIVATION THROUGH A TLR9-MEDIATED MECHANIS...
115 - 5-ASA MEDICATION COMPLIANCE: A QUESTION OF PREFERENCE
116 - THE IMPACT OF CROHN’S DISEASE (CD) AND TREATMENT WITH CERTOLIZUMAB PEGOL (CZP) 400MG EVERY 4 WE...
117 - IDIOPATHIC THROMBOCYTOPENIC PURPURA OCCURRING AFTER TOTAL ABDOMINAL COLECTOMY FOR PEDIATRIC ULC...
118 - THE COMMENSAL BACTERIA LACTOBACILLUS PLANTARUM SECRETES SOLUBLE FACTORS WHICH INHIBIT NF...
119 - VASOACTIVE INTESTINAL PEPTIDE AMELIORATES BARRIER DYSFUNCTION ASSOCIATED WITH ATTACHING EFFACIN...
120 - MATERNAL DIET ALTERS INTESTINAL PHYSIOLOGY AND SENSITIVITY TO EXPERIMENTAL COLITIS IN OFFSPRING...
121 - PATIENTS WITH INFLAMMATORY BOWEL DISEASE EXHIBIT DYSREGULATED RESPONSES TO TLR9 AGONISTS IN COL...
122 - NOD PROTEIN FUNCTION IN REGULATING MUCOSAL IMMUNTY
123 - PROGRESSION OF DIVERTICULAR COLITIS TO CLASSICAL ULCERATIVE COLITIS
124 - DELETION OF CD47 PROTECTS FROM MURINE EXPERIMENTAL CROHN’S DISEASE